Alpha Pro Tech (APT) Competitors

$6.08 -0.27 (-4.25%)

Closing price 04:00 PM Eastern

Extended Trading

$6.17 +0.09 (+1.48%)

As of 07:56 PM Eastern

APT vs. OBIO, RXST, ELMD, EMBC, and LUCD

Should you buy Alpha Pro Tech stock or one of its competitors? MarketBeat compares Alpha Pro Tech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Pro Tech include Orchestra BioMed (OBIO), RxSight (RXST), Electromed (ELMD), Embecta (EMBC), and Lucid Diagnostics (LUCD). These companies are all part of the "medical equipment" industry.

How does Alpha Pro Tech compare to Orchestra BioMed?

Alpha Pro Tech (NYSE:APT) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Alpha Pro Tech has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

In the previous week, Orchestra BioMed had 3 more articles in the media than Alpha Pro Tech. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Alpha Pro Tech. Orchestra BioMed's average media sentiment score of 0.49 beat Alpha Pro Tech's score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Pro Tech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Pro Tech has a net margin of 6.99% compared to Orchestra BioMed's net margin of -166.96%. Alpha Pro Tech's return on equity of 6.70% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Pro Tech	6.99%	6.70%	5.76%
Orchestra BioMed	-166.96%	-167.93%	-62.44%

Alpha Pro Tech has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Pro Tech	$59.91M	1.04	$4.19M	$0.35	17.37
Orchestra BioMed	$33.48M	7.26	-$52.70M	-$1.13	N/A

Orchestra BioMed has a consensus price target of $14.50, indicating a potential upside of 257.14%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

22.7% of Alpha Pro Tech shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 15.0% of Alpha Pro Tech shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alpha Pro Tech beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to RxSight?

RxSight (NASDAQ:RXST) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

RxSight has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

In the previous week, RxSight had 7 more articles in the media than Alpha Pro Tech. MarketBeat recorded 10 mentions for RxSight and 3 mentions for Alpha Pro Tech. Alpha Pro Tech's average media sentiment score of 0.00 beat RxSight's score of -0.25 indicating that Alpha Pro Tech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Pro Tech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Pro Tech has a net margin of 6.99% compared to RxSight's net margin of -36.58%. Alpha Pro Tech's return on equity of 6.70% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Alpha Pro Tech	6.99%	6.70%	5.76%

Alpha Pro Tech has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.71	-$38.94M	-$1.13	N/A
Alpha Pro Tech	$59.91M	1.04	$4.19M	$0.35	17.37

RxSight presently has a consensus price target of $9.44, indicating a potential upside of 70.17%. Given RxSight's stronger consensus rating and higher probable upside, research analysts clearly believe RxSight is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

78.8% of RxSight shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 15.0% of Alpha Pro Tech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

RxSight and Alpha Pro Tech tied by winning 8 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to Electromed?

Electromed (NYSE:ELMD) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Electromed has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

40.8% of Electromed shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 15.0% of Alpha Pro Tech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Electromed had 2 more articles in the media than Alpha Pro Tech. MarketBeat recorded 5 mentions for Electromed and 3 mentions for Alpha Pro Tech. Electromed's average media sentiment score of 0.39 beat Alpha Pro Tech's score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Pro Tech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Electromed has a net margin of 11.34% compared to Alpha Pro Tech's net margin of 6.99%. Electromed's return on equity of 15.71% beat Alpha Pro Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Alpha Pro Tech	6.99%	6.70%	5.76%

Electromed has higher revenue and earnings than Alpha Pro Tech. Alpha Pro Tech is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$68.86M	4.09	$5.15M	$1.03	33.04
Alpha Pro Tech	$59.91M	1.04	$4.19M	$0.35	17.37

Electromed presently has a consensus price target of $37.50, indicating a potential upside of 10.20%. Given Electromed's stronger consensus rating and higher probable upside, research analysts clearly believe Electromed is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Electromed beats Alpha Pro Tech on 14 of the 16 factors compared between the two stocks.

How does Alpha Pro Tech compare to Embecta?

Embecta (NASDAQ:EMBC) and Alpha Pro Tech (NYSE:APT) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Embecta has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Alpha Pro Tech has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Embecta presently has a consensus price target of $15.00, indicating a potential upside of 380.77%. Given Embecta's stronger consensus rating and higher probable upside, equities analysts clearly believe Embecta is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Embecta had 6 more articles in the media than Alpha Pro Tech. MarketBeat recorded 9 mentions for Embecta and 3 mentions for Alpha Pro Tech. Alpha Pro Tech's average media sentiment score of 0.00 beat Embecta's score of -0.16 indicating that Alpha Pro Tech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alpha Pro Tech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Alpha Pro Tech. Embecta is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.17	$95.40M	$1.90	1.64
Alpha Pro Tech	$59.91M	1.04	$4.19M	$0.35	17.37

93.8% of Embecta shares are owned by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 15.0% of Alpha Pro Tech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Embecta has a net margin of 10.73% compared to Alpha Pro Tech's net margin of 6.99%. Alpha Pro Tech's return on equity of 6.70% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Alpha Pro Tech	6.99%	6.70%	5.76%

Summary

Embecta beats Alpha Pro Tech on 10 of the 15 factors compared between the two stocks.

How does Alpha Pro Tech compare to Lucid Diagnostics?

Alpha Pro Tech (NYSE:APT) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Alpha Pro Tech has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

22.7% of Alpha Pro Tech shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 15.0% of Alpha Pro Tech shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lucid Diagnostics has a consensus price target of $4.13, indicating a potential upside of 304.41%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Alpha Pro Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Pro Tech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Lucid Diagnostics had 3 more articles in the media than Alpha Pro Tech. MarketBeat recorded 6 mentions for Lucid Diagnostics and 3 mentions for Alpha Pro Tech. Lucid Diagnostics' average media sentiment score of 0.13 beat Alpha Pro Tech's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Pro Tech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Pro Tech has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Pro Tech	$59.91M	1.04	$4.19M	$0.35	17.37
Lucid Diagnostics	$4.71M	42.28	-$58.01M	-$0.96	N/A

Alpha Pro Tech has a net margin of 6.99% compared to Lucid Diagnostics' net margin of -1,426.27%. Alpha Pro Tech's return on equity of 6.70% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Pro Tech	6.99%	6.70%	5.76%
Lucid Diagnostics	-1,426.27%	N/A	-95.51%

Summary

Alpha Pro Tech and Lucid Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

Get Alpha Pro Tech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APT vs. The Competition

Export

Metric	Alpha Pro Tech	Surgical appliances & supplies Industry	Industrials Sector	NYSE Exchange
Market Cap	$62.12M	$24.41M	$9.29B	$22.96B
Dividend Yield	N/A	N/A	3.57%	4.07%
P/E Ratio	16.43	16.43	24.80	28.29
Price / Sales	1.04	1.41	5,418.94	25.21
Price / Cash	12.80	12.80	27.92	25.11
Price / Book	1.15	1.45	4.78	4.73
Net Income	$4.19M	-$3.92M	$792.39M	$1.07B
7 Day Performance	29.36%	2.83%	0.93%	-1.74%
1 Month Performance	33.92%	10.00%	4.39%	2.05%
1 Year Performance	32.75%	-30.95%	38.22%	23.46%

Alpha Pro Tech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APT Alpha Pro Tech	N/A	$6.08 -4.3%	N/A	+40.2%	$62.12M	$59.91M	16.43	120	Insider Trade High Trading Volume
OBIO Orchestra BioMed	3.5392 of 5 stars	$4.05 +3.1%	$14.25 +251.9%	+53.2%	$242.51M	$33.48M	N/A	4	News Coverage Earnings Report Analyst Forecast
RXST RxSight	2.7024 of 5 stars	$5.80 -0.1%	$9.44 +62.9%	-59.9%	$240.66M	$134.48M	N/A	220
ELMD Electromed	1.3124 of 5 stars	$26.78 -0.3%	$36.67 +36.9%	+21.2%	$221.56M	$68.86M	35.70	160	News Coverage Analyst Forecast
EMBC Embecta	4.1292 of 5 stars	$3.66 +1.5%	$15.00 +310.4%	-72.5%	$216.85M	$1.08B	1.92	1,850

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:APT) was last updated on 5/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Pro Tech (APT) Competitors

APT vs. OBIO, RXST, ELMD, EMBC, and LUCD

How does Alpha Pro Tech compare to Orchestra BioMed?

Summary

How does Alpha Pro Tech compare to RxSight?

Summary

How does Alpha Pro Tech compare to Electromed?

Summary

How does Alpha Pro Tech compare to Embecta?

Summary

How does Alpha Pro Tech compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APT vs. The Competition

Alpha Pro Tech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Pro Tech (APT) Competitors

APT vs. OBIO, RXST, ELMD, EMBC, and LUCD

How does Alpha Pro Tech compare to Orchestra BioMed?

Which has more volatility & risk, APT or OBIO?

Does the media favor APT or OBIO?

Is APT or OBIO more profitable?

Which has higher earnings and valuation, APT or OBIO?

Do analysts recommend APT or OBIO?

Do insiders and institutionals believe in APT or OBIO?

Summary

How does Alpha Pro Tech compare to RxSight?

Which has more risk and volatility, RXST or APT?

Does the media refer more to RXST or APT?

Is RXST or APT more profitable?

Which has better valuation and earnings, RXST or APT?

Do analysts rate RXST or APT?

Do institutionals and insiders have more ownership in RXST or APT?

Summary

How does Alpha Pro Tech compare to Electromed?

Which has more risk and volatility, ELMD or APT?

Do institutionals and insiders have more ownership in ELMD or APT?

Does the media refer more to ELMD or APT?

Is ELMD or APT more profitable?

Which has better valuation and earnings, ELMD or APT?

Do analysts rate ELMD or APT?

Summary

How does Alpha Pro Tech compare to Embecta?

Which has more volatility & risk, EMBC or APT?

Do analysts rate EMBC or APT?

Does the media refer more to EMBC or APT?

Which has preferable valuation & earnings, EMBC or APT?

Do insiders & institutionals have more ownership in EMBC or APT?

Is EMBC or APT more profitable?

Summary

How does Alpha Pro Tech compare to Lucid Diagnostics?

Which has more volatility and risk, APT or LUCD?

Do insiders & institutionals have more ownership in APT or LUCD?

Do analysts rate APT or LUCD?

Does the media prefer APT or LUCD?

Which has higher valuation and earnings, APT or LUCD?

Is APT or LUCD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APT vs. The Competition

Alpha Pro Tech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools